he reviews in this issue of the European Respiratory Review highlight the continued evolution of the PAH field. Within the next few years drugs will be available that have a demonstrated effect on the clinically relevant outcomes of morbidity and mortality, with new pathways emerging as potential targets for continuing pre-clinical research. Such progress must continue if PAH is to eventually become a curable disease.
L. J. Rubin, N. Galie, G. Simonneau, V. McLaughlin (2013). A paradigm shift in pulmonary arterial hypertension management. EUROPEAN RESPIRATORY REVIEW, 22, 423-426 [10.1183/09059180.00006913].
A paradigm shift in pulmonary arterial hypertension management
GALIE', NAZZARENO;
2013
Abstract
he reviews in this issue of the European Respiratory Review highlight the continued evolution of the PAH field. Within the next few years drugs will be available that have a demonstrated effect on the clinically relevant outcomes of morbidity and mortality, with new pathways emerging as potential targets for continuing pre-clinical research. Such progress must continue if PAH is to eventually become a curable disease.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
423.full.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale / Version Of Record
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione
246.99 kB
Formato
Adobe PDF
|
246.99 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
